Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.

In this case study, the progression of alopecia universalis in a Japanese man was linked to the involvement of Th1 and Th17 cells, suggesting an autoimmune mechanism.

This study presents a reported case where dupilumab treatment for atopic dermatitis led to improvement in alopecia universalis.

This case report describes successful treatment of alopecia universalis associated with severe hyperthyroidism using azathioprine and hydroxychloroquine after poor response to oral steroid therapy.

This study found that scanning electron microscopy can identify four specific hair morphology patterns in alopecia areata patients, offering a less invasive diagnostic option compared to punch biopsy.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

This case report presents the first instance of a pediatric alopecia areata patient switching from baricitinib to ritlecitinib, demonstrating favorable clinical outcomes, suggesting a potential new treatment pathway for children with severe cases of this condition.

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

This case report documented a 20-year-old male with alopecia areata who experienced slight hair regrowth following treatment with cyclosporine and methylprednisolone, highlighting the importance of individualized treatment plans and consideration of medication side effects.

This case study reports a young male with alopecia universalis experienced significant hair whitening following baricitinib treatment, highlighting the need for further research on JAK inhibitors' impact on hair pigmentation and their underlying mechanisms.

This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.

This review summarizes methods for creating alopecia areata animal models and reports no new results, emphasizing that improved evaluation and combined disease models are needed for future research.

This case study describes a man with long-standing alopecia universalis who experienced hair regrowth after taking testosterone, chorionic gonadotropin, and DHEA-S.

This case report identifies alopecia universalis as a probable adverse drug reaction to adalimumab in a patient with psoriasis and psoriatic arthritis.

This report describes a rare case of alopecia areata universalis developing in a child during the recovery phase of phenobarbital-induced anti-convulsant hypersensitivity syndrome, which suggests a mechanism involving lymphocyte-related immune responses.

This study surveyed dermatologists in Greece and Italy and found significant variability and challenges in the diagnosis and treatment of alopecia areata, including limited use of severity scores and diverse treatment approaches, particularly for special site involvement and chronic cases.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This study found that trichoscopy aided in assessing treatment responses for patchy alopecia areata, with both intralesional corticosteroids and platelet-rich plasma showing effectiveness, but only PRP significantly improved patient symptom impact scores.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

This review discusses the use of topical and intralesional corticosteroids for treating alopecia areata, highlighting their efficacy and safety but noting recurrence and pain as limitations; no new clinical results are reported.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.